Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma

  title={Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma},
  author={Merryl R. Lobo and Ayaka Kukino and Huong Tran and Matthias C. Schabel and Charles S. Springer and G. Yancey Gillespie and Marjorie R. Grafe and Randall L. Woltjer and Martin M. Pike},
  journal={PLoS ONE},
Prognosis remains extremely poor for malignant glioma. Targeted therapeutic approaches, including single agent anti-angiogenic and proteasome inhibition strategies, have not resulted in sustained anti-glioma clinical efficacy. We tested the anti-glioma efficacy of the anti-angiogenic receptor tyrosine kinase inhibitor cediranib and the novel proteasome inhibitor SC68896, in combination and as single agents. To assess anti-angiogenic effects and evaluate efficacy we employed 4C8 intracranial… Expand
The role of Cediranib in ovarian cancer
Cediranib is currently being explored in ovarian cancer and other gynaecological malignancies aiming to improve patient care; further research will help define its role in standard clinical practice for patients with ovarian cancer. Expand
Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma
The available knowledge concerning immune composition, stem cell characteristics and response to standard-of-care and immunotherapeutics for the most commonly available immunocompetent mouse models of GBM is summarized. Expand
Co-Administered Polymeric Nano-Antidotes for Improved Photo-Triggered Response in Glioblastoma
The major goal of this research was to investigate a new combination of photodynamic-chemotherapy drugs in nano-formulation for increased efficacy in glioblastoma treatment at reduced concentrations of therapeutics for enhanced drug delivery in vitro. Expand
Correlation analysis of the clinicopathological features of glioma and expression of p 53 and VEGF
Glioma is a common type of brain and neurological cancer with high degree of malignancy. Expression of p53 has been found in a variety of tumor cells and VEGF has been associated with theExpand
Shutter-Speed DCE-MRI Analyses of Human Glioblastoma Multiforme (GBM) Data.
Within the proposed SSM analysis framework, kio and kbo could be estimated, which might be useful biomarkers for GBM diagnosis and survival prediction in future, and indicate that CA and water molecule have different transmembrane pathways. Expand
Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model.
The data suggest the relative stability of these MR indices of tumor microenvironment over a 24h duration in this gliosarcoma model. Expand
Using 1H2O MR to measure and map sodium pump activity in vivo.
Preliminary results suggest a non-invasive way to measure the cell number density, the mean cell volume, and the cellular NKA metabolic rate with high spatial resolution, and initial findings indicate their absolute values can be determined. Expand


Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Combined cediranib/quinacrine treatment synergistically increased antivascular/antitumor efficacy in intracranial 4C8 mouseglioma, suggesting a promising and facile treatment strategy for malignant glioma. Expand
Antiangiogenic therapies for high-grade glioma
This Review presents the rationale and clinical trial evidence for targeting angiogenesis in HGGs, focusing predominantly on agents that target vascular endothelial growth factor (VEGF) and its receptors. Expand
SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo
SC68896 is the first proteasome inhibitor that exerts antiglioma activity in vivo and may represent a novel prototype agent for the treatment of malignant gliomas and warrants clinical evaluation. Expand
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
  • W. Kamoun, C. D. Ley, +10 authors R. Jain
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
By controlling edema, cediranib significantly increased survival of mice in the face of persistent tumor growth, suggesting anti-VEGF agents may be able to improve survival of patients with glioblastoma, even without inhibiting tumor growth. Expand
Primetime for antiangiogenic therapy
The results of recent clinical trials in the treatment of gliomas are summarized, mechanisms of resistance arising under angiogenesis inhibition are pointed towards, and the challenges for the future are discussed. Expand
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
This study is the first to demonstrate that bortezomib, at a clinically relevant dose, did not have any effect on the apoptosis and proliferation of malignant gliomas in vivo. Expand
In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.
Cediranib efficacy was shown to associate with higher cytostatic and unique cytotoxic effects in vitro and both antitumoral and antiangiogenic activity in vivo, which could associate with its great capacity to inhibit mitogen-activated protein kinase (MAPK) and AKT pathways. Expand
Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
Recent anti-angiogenic therapy for malignant glioma is reviewed and implantable devices and nano/microparticles are highlighted as next-generation methods for chemotherapeutic delivery. Expand
Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
Findings provide compelling evidence that autophagic vacuole accumulation plays a causal role in the anti-glioma cytotoxic efficacy of combined cediranib/quinacrine therapy for malignant glioma. Expand
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies
This review summarizes the currently implemented single-agent and combination molecularly targeted therapies for MG and concludes that it is unlikely that any single agent will have efficacy in more than a subset of tumors. Expand